Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 7/20 | 0.49 |
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | CD44 | P16070 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6347388 | 0.74 | ASIC3 (0.65) | ASIC3CD274PNMTCD44MAOB | |
| SCHEMBL25404881 | 0.74 | ASIC3 (0.54) | ASIC3CD274PNMTCD44MAOB | |
| SCHEMBL13757752 | 0.73 | HTR6 (0.53) | PNMTCA2DRD2DRD3 | |
| SCHEMBL32677328 | 0.73 | APP (0.81) | ASIC3APPHSD17B1HSD17B2ERN1 | |
| SCHEMBL27159530 | 0.73 | APP (0.81) | ASIC3APPHSD17B1HSD17B2ERN1 | |
| Hydrochloric Acid SCHEMBL9957809 | 0.72 | HTR6 (0.52) | PNMTCA2DRD2DRD3 | |
| SCHEMBL25402840 | 0.71 | CD274 (0.61) | ASIC3CD274PNMTCD44MAOB | |
| SCHEMBL13291990 | 0.71 | APP (0.54) | APPCD274HSD17B1HSD17B2ERN1 | |
| SCHEMBL25407596 | 0.71 | ASIC3 (0.54) | ASIC3CD274PNMTCD44MAOB | |
| SCHEMBL28813263 | 0.71 | APP (0.67) | ASIC3APPHSD17B1HSD17B2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529321-B2 | Use of aminomethylenecyclohexane-1,3-dione compound | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-12-20 | — | — | US | disclosed |
| US-20200170966-A1 | USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200170966-A1 | USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND | ATG7, BECN1, SQSTM1 | ASIC3 3380/4885APP 2479/4885CD274 4255/4885 |
| US-11529321-B2 | Use of aminomethylenecyclohexane-1,3-dione compound | ATG7, BECN1, SQSTM1 | ASIC3 3380/4885APP 2479/4885CD274 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.